title: Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
abstract: Twenty-nine elderly patients who failed treatment with clozapine, risperidone, or olanzapine entered this 24-week, single-center, open-label trial to assess the efficacy of quetiapine (12.5-400 mg/day) for psychosis in patients with Parkinson's disease (PD). Psychiatric, motor, and cognitive assessments were administered at baseline and at periodic intervals for 24 weeks. These included the Brief Psychiatric Rating Scale (BPRS), Neuropsychiatric Inventory (NPI), Unified Parkinson's Disease Rating Scale (UPDRS) and tests of intellectual functioning, attention, and memory. Repeated measures statistical analysis was used to assess change from baseline. The results revealed significant improvements in the 24-week BPRS total score and NPI psychosis subscale scores, with no decline in UPDRS total or motor subscale scores. There was also significant improvement in recall scores on cognitive measures. These results indicate that quetiapine may treat psychotic symptoms and improve cognition without worsening motor function in patients with PD, suggesting that quetiapine is an effective and well-tolerated antipsychotic in this population.
authors.affiliation: Neurology Department, Emory University, Atlanta, Georgia 30329, USA. jjuncos@emory.edu
authors.forename: Jorge L
authors.initials: JL
authors.lastname: Juncos
authors.forename: Vicki J
authors.initials: VJ
authors.lastname: Roberts
authors.forename: Marian L
authors.initials: ML
authors.lastname: Evatt
authors.forename: Rita D
authors.initials: RD
authors.lastname: Jewart
authors.forename: Colleen D
authors.initials: CD
authors.lastname: Wood
authors.forename: Larry S
authors.initials: LS
authors.lastname: Potter
authors.forename: Hann-Chang
authors.initials: HC
authors.lastname: Jou
authors.forename: Paul P
authors.initials: PP
authors.lastname: Yeung
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010054:Brief Psychiatric Rating Scale; D003702:Delusions / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006212:Hallucinations / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D011605:Psychoses, Substance-Induced / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D000069348:Quetiapine Fumarate
chemical_list: D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D007980:Levodopa